Amarin aims for Vascepa boom with doubled sales force nearly in place
Amarin's Vascepa received a heart-helping FDA nod in late December. (Amarin)
Amarin scored an FDA win with blockbuster potential last year when its fish oil-derivative Vascepa received a heart-helping nod on top of statins. Now, with Amarin's fleshed out salesforce nearly in place and prescriptions soaring, the drugmaker is ready to take Vascepa to the next level.
Amarin closed 2019 with a whopping 87% increase in revenue to $429 million, riding skyrocketing prescriptions for Vascepa, which jumped 78% on the year, the company said Wednesday.
In a fourth-quarter earnings call with analysts, CEO John Thero said Amarin's doubled salesforce of 800 reps was nearly in place and ready to capitalize on the FDA's label expansion of Vascepa in December to include a risk reduction of cardiovascular events in patients with abnormally high triglycerides.
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT
Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.
"I think we've hired terrific people," Thero said. "We've got terrific managers, the launch materials are crisp, it's nice to be out with an FDA label, which makes the description of what we're doing much easier. I think the other promotional materials and particularly the DTC advertising, I think it's going to help lift things considerably."